Akili, Inc. (NASDAQ:AKLI) Short Interest Update

Akili, Inc. (NASDAQ:AKLI) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 176,100 shares, a drop of 78.5% from the February 29th total of 820,000 shares. Based on an average daily volume of 2,300,000 shares, the short-interest ratio is presently 0.1 days. Approximately 0.4% of the shares of the company are sold short.

Institutional Investors Weigh In On Akili

Institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC acquired a new stake in Akili during the 3rd quarter worth about $32,000. Geode Capital Management LLC boosted its position in Akili by 55.0% during the 4th quarter. Geode Capital Management LLC now owns 38,504 shares of the company’s stock worth $43,000 after acquiring an additional 13,657 shares during the period. CIBC Asset Management Inc acquired a new stake in Akili during the 1st quarter worth about $56,000. Vanguard Group Inc. boosted its position in Akili by 138.2% during the 3rd quarter. Vanguard Group Inc. now owns 103,200 shares of the company’s stock worth $57,000 after acquiring an additional 59,884 shares during the period. Finally, Cetera Investment Advisers acquired a new stake in shares of Akili during the 2nd quarter valued at about $94,000. 53.12% of the stock is currently owned by institutional investors and hedge funds.

Akili Price Performance

Shares of AKLI opened at $0.29 on Thursday. The firm has a market capitalization of $22.79 million, a price-to-earnings ratio of -0.38 and a beta of 2.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.02 and a current ratio of 6.02. Akili has a one year low of $0.19 and a one year high of $1.67. The stock’s fifty day moving average is $0.29 and its 200-day moving average is $0.42.

Akili (NASDAQ:AKLI) last released its earnings results on Thursday, February 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.12. Akili had a negative return on equity of 76.34% and a negative net margin of 3,545.47%. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $1.07 million. Equities analysts anticipate that Akili will post -0.53 EPS for the current year.

About Akili

Akili, Inc, a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.